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Summary
Background: Secretory carcinoma (SC) of the breast is a rare and indolent tumor. Although
originally described in children, it is now known to occur in adults of both sexes. Recently, the
tumor was associated with the ETV6-NTRK3 gene translocation.
Case presentation: A 52-year-old male was diagnosed with secretory breast carcinoma and
underwent a modified radical mastectomy. At 18 months the tumor recurred at the chest wall and
the patient developed lung metastases. He was treated concurrently with radiation and
chemotherapy without response. His tumor showed the ETV6-NTRK3 translocation as
demonstrated by fluorescent in situ hybridization (FISH).
Conclusion: SC is a rare slow-growing tumor best treated surgically. There are insufficient data
to support the use of adjuvant radiation or chemotherapy. Its association with the ETV6-NTRK3
fusion gene gives some clues for the better understanding of this neoplasm and eventually, the
development of specific therapies.
Background
SC of the breast is one of the rarest types of breast cancer
accounting for less than 1% of all breast cancers. This
entity was initially termed "Juvenile breast cancer" by
McDivitt and Stewart, based on the fact that the average
age of the seven patients described in their series was nine
year-old with range of three to fifteen years [1]. Subse-
quently, more cases in children [2-6] and adults [7-12]
were described. Therefore, it was recommended that the
descriptive term SC replace the designation "juvenile car-
cinoma". Secretory breast carcinomas have a characteristic
balanced translocation, t(12;15), that creates a ETV6-
NTRK3 gene fusion. The finding of a fusion transcript in
SC and the demonstration that ETV6-NTRK3 could trans-
form murine mammary epithelial cell lines has chal-
lenged widely accepted beliefs on breast carcinogenesis
Published: 17 June 2005
World Journal of Surgical Oncology 2005, 3:35 doi:10.1186/1477-7819-3-
35
Received: 22 March 2005
Accepted: 17 June 2005
This article is available from: http://www.wjso.com/content/3/1/35
© 2005 Arce et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2005, 3:35 http://www.wjso.com/content/3/1/35
Page 2 of 7
(page number not for citation purposes)
[13]. This specific translocation is associated with congen-
ital fibrosarcoma and mesoblastic nephroma, two mor-
phologically similar pediatric mesenchymal tumors with
no epithelial features [14]. The biological consequence of
this translocation is the fusion of the dimerization
domain of a transcriptional regulator (ETV6) with a mem-
brane receptor tyrosine kinase (NTRK3) that activates the
Ras-Mek1 and PI3K-Akt pathways which are important for
breast cell proliferation and survival [15,17]. In only a few
cases of secretory carcinoma the presence of the transloca-
tion has been confirmed. In the seminal report by Tognon
12 out of 13 cases tested positive [13] whereas Makretsov
et al., found 3 out of 4 confirmed secretory carcinomas
cases positive and at the same time screened 481 invasive
breast carcinomas of which only one gave positive signal.
This tumor was later confirmed to be a secretory carci-
noma [16].
Case report
A 52 year-old male presented to our institution having
undergone local excision of a left breast tumor one month
previously. The tumor had measured 7 × 5 cm. The mass
had been present for 10 years. At physical examination
there was evidence of recent surgery and the patient had a
1 cm ipsilateral axillary lymph node. Serum tumor mark-
ers and other routine blood test were normal. The liver
ultrasonography, chest X-ray and bone scan were negative
for metastases.
Tumor was grossly firm and circumscribed (1a) Figure 1
Tumor was grossly firm and circumscribed (1a). The histological pattern was microcystic (1b) with abundant intra and extracel-
lular secretory material as showed by the colloidal iron stain which was diffuse and strongly positive (1c). The tumor was posi-
tive for S-100 protein (1d).World Journal of Surgical Oncology 2005, 3:35 http://www.wjso.com/content/3/1/35
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He underwent a modified radical mastectomy. Residual
tumor measuring 2.8 cm × 2.6 cm was present. On macro-
scopic examination the tumor was firm and circumscribed
(Figure 1a). Microscopy showed the classical features of
secretory carcinoma with a microcystic pattern (Figure 1b)
with abundant intra and extracellular secretory material.
No tumor was present at the surgical margins. Colloidal
iron staining highlighted the secretory material (Figure
1c). On immunohistochemistry, the tumor cells were pos-
itive for S-100 protein (Figure 1d) but negative for estro-
gen and progesterone receptor and HER2 (Dako,
Carpinteria, CA). 2 of 24 resected lymph nodes were pos-
itive for metastatic carcinoma.
The case was investigated for the t(12;15) ETV6-NTRK3
translocation using two complementary probe sets [16]. A
t(12;15) translocation fusion probe assay (Fig. 2a) and a
chromosome 15 NTRK3 gene split-apart assay (Fig. 2b)
were used to detect the t(12;15) translocation. All BAC
clones used in this study were obtained from the BACPAC
Resources Centre at the Children's Hospital Oakland
Research Institute. All probes were labeled by nick transla-
tion with the use of the manufacturer's recommended
protocol (Vysis, Downer's Grove, Illinois). BAC clones
RP11-434C1 and RP11-407P10 telomeric to ETV6 on 12p
were labeled with spectrum orange. On chromosome 15,
RP11-114I9 and RP11-730G13, centromeric to NTRK3 on
15q were labeled with spectrum green and clone RP11-
247E14, telomeric to NTRK3 was labeled with spectrum
orange. Six-micrometer tissue sections were baked over-
night at 60C and then subjected to FISH with a modified
protocol (Vysis, Downers Grove, IL) [14]. FISH signals
were analyzed with a Zeiss Axioplan fluorescent micro-
scope equipped with a COHU-CCD camera. Images were
captures with Metasystems ISIS software (MetaSystems
Group Inc., Belmont MA) with seven focal planes stacked
for the analysis.
In view of the nodal metastasis it was decided to treat the
patient with six courses of adjuvant 5-fluorouracil, adri-
amycin and cyclophosphamide (FAC). The patient aban-
doned treatment after the second course. The patient
returned to clinic eighteen months later with two hard
nodules in the surgical resection area measuring 8 × 8 cm
and 4 cm × 4 cm, (one ulcerated), and three left axillary
subcutaneous nodules, two measuring 2 × 2 cm and one
3 × 3 cm (Figure 3a).
A chest CT scan identified pulmonary metastases with a
right pleural effusion (Fig. 3b). The effusion was drained
via percutaneous thoracentesis. He then began treatment
with concurrent radiation (total dose of 60 Gy) and UFT
FISH images confirming the presence of the t(12;15) Figure 2
FISH images confirming the presence of the t(12;15). In 2a, the presence of the ETV6-NTRK3 fusion is demonstrated by the 
close proximity of a red signal (ETV6 from chromosome 12) with a green signal (NTRK3 from chromosome 15) in each cell. In 
2b, each cell shows separation of red and green probes flanking the NTRK3 gene from chromosome 15.World Journal of Surgical Oncology 2005, 3:35 http://www.wjso.com/content/3/1/35
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(Tegafur-Uracil) to the chest followed by systemic UFT as
a single agent for 3 months. Post-treatment, there was no
change in the pulmonary disease and there was minor
response of chest-wall and axillary disease (Figure 4a and
4b).
Discussion
Secretory carcinoma is a very rare type of breast carci-
noma. Lamovec and Bracko [18] reported 4 cases of SC in
a retrospective series of 7038 breast carcinoma cases, and
Botta et al [19] found one case of SC among 3000 breast
carcinoma cases.
Disease recurrence at the chest wall (3a) and lung metastasis (3b) Figure 3
Disease recurrence at the chest wall (3a) and lung metastasis (3b). There were two hard nodules in the chest wall and three 
ipsilateral axillary nodules. In the lung several nodular metastases were present as well as a right sided pleural effusion.
Disease in the chest wall (4a) and lung (4b) after radiation and concurrent chemotherapy Figure 4
Disease in the chest wall (4a) and lung (4b) after radiation and concurrent chemotherapy. There was only minor response in 
the chest wall disease and essentially no change in the lung.World Journal of Surgical Oncology 2005, 3:35 http://www.wjso.com/content/3/1/35
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The age at presentation varies from 3 to 87 years with a
median age of 25 years [1,5-11]. The male-female ratio is
approximately 1:6 [20,21]. The case presented herein is
extremely unusual as SC, particularly metastatic SC, has
rarely been reported in males. Literature search identified
only 16 other cases of SC in males. Our case was older
than the average age reported for secretory carcinoma in
males which is 17 years. Only the case reported by Kuwa-
bara was older than our case (66 years) [22,23]. Table 1
summarizes the main clinical features of the cases of SC
reported in males.
SC's can demonstrate several histological patterns includ-
ing, solid, microcystic, and ductal, with many tumors con-
taining all three patterns [24]. The tumor cells are
polygonal with granular eosinophilic cytoplasm. Atypia is
minimal or absent and mitotic activity is low [20]. A typ-
ical finding is the presence of intracellular and extracellu-
lar secretions [7]. This secretory material is periodic acid-
Schiff and alcian blue positive [24,25]. In this tumor there
was no expression of steroid receptors or HER2. A recent
study has reported than only 4 and 2 out of 13 cases
expressed the estrogen and progesterone receptor respec-
tively and only two were HER2 positive [26]. In the cur-
rent case, the tumor had the t(12;15) ETV6-NTRK3 fusion
gene (Fig. 4).
The most frequent clinical presentation is of an asympto-
matic mobile mass, which is usually subareolar. The
tumor size varies from 1 cm to 16 cm with an average
diameter of 3 cm. [7,16]. Our patient had a mass of 7 cm
× 5 cm. As the patient reported that the lesion had been
present for at least 10 years, it had behaved in a slow grow-
ing, indolent fashion. This is supported by other reported
cases [20]. In this regard, Biallo et al., have reported a
MIB1 labeling index of 11.4% (range: <1 to 34%) [26].
Surgery is considered the primary treatment of secretory
carcinoma, however, due to scarcity of reported cases no
published guidelines for surgical management exist. There
are however, many cases reported of patients who had suf-
fered a local recurrence, therefore mastectomy appears to
be a sound surgical choice [1,5,7,9-11,22,24,25]. There
are no data however on conservative treatment but this
option could be explored particularly in cases where
breast development has not yet occurred. In regard to the
management of the axilla, the overall incidence of axillary
lymph node infiltration is around 30% in children and
adults regardless of gender [21,24], hence axillary lymph
node dissection is advocated by some authors for tumors
≥ 2 cm [7,24]. Nevertheless, sentinel node biopsy, may be
useful for secretory carcinomas. A recent report on a 9-
year-old girl treated with simple mastectomy and axillary
sentinel lymph node biopsy shows that this is feasible
[27].
Table 1: Data on 17 males with Secretory Breast Cancer
Author Year Age Duration of 
symptoms
Size (cm) Axillary 
status
Treatment Hormone 
Receptors
ETV6-
NTRK3
Follow-up
Simpson31 1969 5 ND ND - (clinical) LE NE NE NED 4y
Tavassolli7 1980 9 ND ND - (clinical) LE NE NE NED 1.75y
Kari5 1985 3 1 mo 1.5 + (1/4) SM+ALNS NE NE ND
Roth32 1988 23 21y 2.0 - (0/21) MRM NE NE NED 4y
Krausz10 1989 24 Many years 4.0 ND SM + RT (axilla) NE NE DOD 20y
Serour21 1992 17 4 y 1.5 - (0/3) WLE + ALND ER- PR+ NE NED 5y
Lamovec18 1994 20 ND 1.2 - (0/?) MRM ER+ PR+ NE NED 1y
Pohar-Marinsek33 1994 20 6–7 y 1.2 - (clinical) SM ER+ PR+ NE NED 6 m
Kuwabara34 1988 66 3 y 3.0 + (2/?) MRM ER- PR+ NE NED 8 m
Vesoulis35 1998 33 10 y 1.5 ND MRM ER+ PR+ NE ND
Kameyama36 1998 50 ND 3.0 - (0/?) MRM ER+ NE ND
Chevallier37 1999 9 14 m 2.0 - (0/?) LE + ALND ER- PR- NE NED 45 m
Yildirim38 1999 11 1 y 1.5 + (1/18) MRT + CT+ RT ER - NE NED 12 m
Bhagwandeen39 1999–2000 9 1 m 1.2 - (0/15) MRM ER- PR- NE NED 20 m
De Bree22 2001 17 2 y 2.0 - (0–14) MRM ER- PR- NE NED 9 m
Grabellus40 2005 46 Male-
female 
transexual
ND 4.0 ND LE ER- PR- PRESENT ND
This case 2005 52 10 y 7 + 2/24 MRM + CT ER- PR- PRESENT AWD 25 m
ND: no defined, LE: Local excision, MRM: Modified Radical Mastectomy, CT: chemotherapy, RT Radiotherapy, NE: not examined, NED: not 
evidence of disease, AWD: Alive with disease, ER: estrogen receptor, PR progesterone receptor. SM simple mastectomy, ALNS: axillary lymph 
node sampling, ALND: axillary lymph node dissection, WLE: wide local excision, DOD: Died of disease.World Journal of Surgical Oncology 2005, 3:35 http://www.wjso.com/content/3/1/35
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Postoperative radiotherapy [19,21] and adjuvant chemo-
therapy [7,28] have been used on at least two occasions.
There is at present insufficient evidence to recommend
either approach in the management of secretory
carcinoma.
Local recurrence after a long disease-free interval has been
described in numerous cases; [1-3,5,9,11,28] however
these occurred in patients that underwent conservative
surgery. This is the second case reported with chest wall
recurrence after mastectomy. In the other case the patient
was treated with wide local excision and she is alive at 11-
month follow-up. In contrast, our case also presented dis-
tant recurrence [12].
Distant metastases from secretory carcinoma are
extremely rare with only four cases reported [20]. Our case
is the fifth case who developed distant metastases, this,
despite having only two positive lymph nodes at resec-
tion. Another recently reported patient remained disease
free at a follow-up of 13 months despite having 12 out of
14 positive nodes and not having received adjuvant chem-
otherapy [23].
There are several reported cases of patients with secretory
breast carcinoma with distant metastases who were
treated with either single agent or combination chemo-
therapy without success. Among the drugs reported are 5-
FU, vindesine, mitomycin and prednisone, adriamycin,
epirubicin, cyclophosphamide, carboplatin, and even
newer active agents such as docetaxel. These data clearly
show that this neoplasm is not chemosensitive, as all of
the patients treated with chemotherapy showed disease
progression while on treatment [7,10,20] and [29]. In our
case, despite using UFT alone and with concomitant radi-
otherapy there was no response. These observations are in
contrast with reports on the high chemosensitivity to
common agents (vincristine, cyclophosphamide, adri-
amycin, dactinomycin and ifosfamide) for congenital fib-
rosarcomas and mesoblastic nephromas, two other
neoplasms associated with the translocation ETV6-NTRK3
[30]. This suggests that secretory breast carcinoma, due
perhaps to its slow growing behavior, acquires additional
genetic alterations than ultimately confer chemoresist-
ance. It will be very useful to establish cancer cell lines
from this tumor type to study whether the chemoresist-
ance is a general phenomenon or drug specific.
Conclusion
Secretory carcinoma is a rare slow-growing tumor that is
best approached by surgical treatment. There are insuffi-
cient data to support the use of adjuvant radiation and/or
chemotherapy. Its association to the ETV6-NTRK3 fusion
gene gives some clues for the better understanding of this
neoplasm and may eventually lead to the development of
specific therapies.
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